Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gareth Pryce

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
Multiple Sclerosis and Related Disorders|April 17, 2015
Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouseSarah Al-Izki, Gareth Pryce, Janet K O'Neill, et al.
Glia|August 26, 2018
Increased expression of colony-stimulating factor-1 in mouse spinal cord with experimental autoimmune encephalomyelitis correlates with microglial activation and neuronal lossSvetlana Gushchina, Gareth Pryce, Ping K Yip, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 9, 2005
Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine inductionRachel Harry, Matthew Gegg, Deborah Hankey, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 31, 2006
Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 miceLynsey G Bilsland, James R T Dick, Gareth Pryce, et al.
Journal of Neuroimmunology|June 9, 2005
Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosisGareth Pryce, Janet K O'Neill, J Ludovic Croxford, et al.
Acta Neuropathologica Communications|December 25, 2013
Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosisDavid W Hampton, Andrea Serio, Gareth Pryce, et al.
Journal of Neuroimmunology|November 27, 2007
Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosisJ Ludovic Croxford, Gareth Pryce, Samuel J Jackson, et al.
The American Journal of Pathology|November 5, 2002
A role for caspase-1 and -3 in the pathology of experimental allergic encephalomyelitis : inflammation versus degenerationZubair Ahmed, Anne I Doward, Gareth Pryce, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 9, 2002
Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosisClaire E Walters, Gareth Pryce, Deborah J R Hankey, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|July 12, 2005
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disordersEva de Lago, Javier Fernández-Ruiz, Silvia Ortega-Gutiérrez, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
Multiple Sclerosis and Related Disorders|April 17, 2015
Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouseSarah Al-Izki, Gareth Pryce, Janet K O'Neill, et al.
Glia|August 26, 2018
Increased expression of colony-stimulating factor-1 in mouse spinal cord with experimental autoimmune encephalomyelitis correlates with microglial activation and neuronal lossSvetlana Gushchina, Gareth Pryce, Ping K Yip, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 9, 2005
Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine inductionRachel Harry, Matthew Gegg, Deborah Hankey, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 31, 2006
Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 miceLynsey G Bilsland, James R T Dick, Gareth Pryce, et al.
Journal of Neuroimmunology|June 9, 2005
Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosisGareth Pryce, Janet K O'Neill, J Ludovic Croxford, et al.
Acta Neuropathologica Communications|December 25, 2013
Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosisDavid W Hampton, Andrea Serio, Gareth Pryce, et al.
Journal of Neuroimmunology|November 27, 2007
Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosisJ Ludovic Croxford, Gareth Pryce, Samuel J Jackson, et al.
The American Journal of Pathology|November 5, 2002
A role for caspase-1 and -3 in the pathology of experimental allergic encephalomyelitis : inflammation versus degenerationZubair Ahmed, Anne I Doward, Gareth Pryce, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 9, 2002
Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosisClaire E Walters, Gareth Pryce, Deborah J R Hankey, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|July 12, 2005
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disordersEva de Lago, Javier Fernández-Ruiz, Silvia Ortega-Gutiérrez, et al.
Pageof 7